Castagna L, Bertuzzi A, Nozza A, Siracusano L, Balzarotti M, Magagnoli M, Sarina B, Timofeeva I, Sinnone M, Grimoldi M G, Farè M, Santoro A
Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy.
Bone Marrow Transplant. 2002 Aug;30(4):207-14. doi: 10.1038/sj.bmt.1703626.
The aim of this pilot study was to exploit the graft-versus-tumor potential of allogeneic transplants while improving safety of the procedure. Twelve patients with advanced hematological malignancies and solid tumors underwent a low intensity conditioning regimen (fludarabine and cyclophosphamide) followed by an allogeneic peripheral blood stem cell transplantation. The median time to achieve an absolute neutrophil count of more than 0.5 x 10(9)/l and an untransfused platelet count of more than 20 x 10(9)/l was 15 and 14 days, respectively. The main extra-hematological toxicities were mucositis and infections. Acute graft-versus-host (GVHD) disease was experienced by 62% of evaluable patients (grade II/B or III/C 80%) responsive to steroids. Extensive chronic GVHD was observed in 62% of patients. Non-relapse transplant-related mortality by day +30 was observed in three patients (25%). Eight out of 12 patients were full donor chimeric by day +100. One patient showed a mixed chimerism at day +37 when he died from progressive disease. One patient was in complete remission (CR) before allogeneic transplantation, and after transplantation four patients achieved CR and four experienced progressive disease. Our study confirms that a low intensity conditioning regimen for allogeneic stem cell transplantation is feasible and effective in heavily pretreated patients.
这项初步研究的目的是利用异基因移植的移植物抗肿瘤潜力,同时提高该程序的安全性。12例晚期血液系统恶性肿瘤和实体瘤患者接受了低强度预处理方案(氟达拉滨和环磷酰胺),随后进行异基因外周血干细胞移植。达到绝对中性粒细胞计数超过0.5×10⁹/L和未输血血小板计数超过20×10⁹/L的中位时间分别为15天和14天。主要的血液外毒性是粘膜炎和感染。62%的可评估患者发生了急性移植物抗宿主(GVHD)病(对类固醇有反应的患者中80%为II/B级或III/C级)。62%的患者观察到广泛的慢性GVHD。在+30天时,3例患者(25%)观察到非复发移植相关死亡率。12例患者中有8例在+100天时为完全供体嵌合体。1例患者在+37天时出现混合嵌合体,当时死于疾病进展。1例患者在异基因移植前处于完全缓解(CR)状态,移植后4例患者达到CR,4例患者经历疾病进展。我们的研究证实,对于经过大量预处理的患者,异基因干细胞移植的低强度预处理方案是可行且有效的。